Product Details
| MW: | ~27.5 kDa |
| |
| Source: | Purified from human liver. |
| |
| UniProt ID: | P07858 |
| |
| Formulation: | Liquid. In 50mM sodium acetate, pH 5.0, containing 1mM EDTA. |
| |
| Purity: | ≥95% (SDS-PAGE) |
| |
| Application Notes: | Useful for inhibitor screening, kinetic studies and cleavage of substrates in vitro or in tissue culture. |
| |
| Shipping: | Shipped on Dry Ice |
| |
| Long Term Storage: | -80°C |
| |
| Scientific Background: | Cathepsin B is a lysosomal protease (endopeptidase and dipeptidyl carboxypeptidase) that can also be secreted from the cell and is involved in protein degradation, apoptosis, arthritis, cancer, and Alzheimer’s disease. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Clickable, selective, and cell-permeable activity-based probe of human cathepsin B – Minimalistic approach for enhanced selectivity: A.I. Bhuiyan, et al.; Bioorg. Chem.
117, 105463 (2021),
Abstract;
Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A: C.C. Bippes, et al.; Mol. Ther.
1525, 473 (2021),
Abstract;
Cell penetrable, clickable and tagless activity-based probe of human cathepsin L: D. Dana, et al.; Bioorg. Chem.
85, 505 (2019),
Application(s): Activity assay,
Abstract;
A mechanistic model to predict effects of cathepsin B and cystatin C on β-amyloid aggregation and degradation: T.J. Perlenfein, et al.; J. Biol. Chem.
292, 21071 (2017),
Abstract;
Full Text
Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy: J.J. Bartlett, et al.; Biochem. J.
473, 3769 (2016),
Abstract;
Expression, purification, and characterization of human cystatin C monomers and oligomers: T.J. Perlenfein, et al.; Protein Expr. Purif.
117, 35 (2016),
Abstract;
Full Text
Glucolipotoxicity diminishes cardiomyocyte TFEB and inhibits lysosomal autophagy during obesity and diabetes: P.C. Trivedi, et al.; Biochim. Biophys. Acta
1861, 1893 (2016),
Abstract;
Development of a highly potent, selective, and cell-active Inhibitor of cysteine cathepsin L-A hybrid design approach: D. Dana, et al.; Chem. Commun. (Camb.)
50, 10875 (2014),
Abstract;
Development of cell-active non-peptidyl inhibitors of cysteine cathepsins: D. Dana, et al.; Bioorg. Med. Chem.
21, 2975 (2013),
Application(s): Assay,
Abstract;
Mechanisms of Dendritic Cell Lysosomal Killing of Cryptococcus: C.R. Hole, et al.; Sci. Rep.
2, 739 (2012),
Application(s): Cell Culture,
Abstract;
Full Text
Related Products
